Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Filamon LTD
Psyence Australia Pty Ltd
ViroMissile, Inc.
Dana-Farber Cancer Institute
University of Florida
Tizona Therapeutics, Inc
Essen Biotech
Essen Biotech
Sapience Therapeutics
Daiichi Sankyo
Second Life Therapeutics
Innate Pharma
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Cancer Research UK
NeoTX Therapeutics Ltd.
DualityBio Inc.
Hangzhou DAC Biotechnology Co., Ltd.
Washington University School of Medicine
Fudan University
Sensei Biotherapeutics, Inc.
NGM Biopharmaceuticals, Inc
OncoC4, Inc.
Columbia University
Theratechnologies
Seagen Inc.
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
National Cancer Institute (NCI)
University of Toronto
Eli Lilly and Company
Vincerx Pharma, Inc.
NGM Biopharmaceuticals, Inc
RECORDATI GROUP
Vector Vitale LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
Pfizer
Cedars-Sinai Medical Center
Exelixis
NGM Biopharmaceuticals, Inc
Convalife (Shanghai) Co., Ltd.
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Klus Pharma Inc.